Processing

Please wait...

Settings

Settings

Goto Application

1. WO1990014595 - COMPOSITION AND METHOD TO DETECT SENSITIVITY TO ALPHA INTERFERON THERAPY

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

What is claimed is:

1. The hybridoma designated F 33 (ATCC No. HB 10155).

2. The monoclonal antibody produced by the hybridoma of claim 1.

3. An antigen, the expression of which is associated with the nonresponsiveness of a malignant cell or tumor to alpha interferon therapy, the antigen being characterized by its specific binding to the monoclonal antibody of claim 2.

4. A method of detecting the sensitivity of a malignant cell or tissue to alpha interferon therapy which comprises contacting a sample of the malignant cell or tissue with a monoclonal antibody which recognizes an epitope of gp 160 cell surface antigen under conditions such that an antibody-antigen complex is formed between the monoclonal antibody and the gp 160 cell surface antigen, if the antigen is present in the sample; and detecting any complex so formed, the absence of complex indicating that the malignant cell or tissue is sensitive to alpha interferon therapy.

5. A method of claim 4, wherein the monoclonal antibody is the monoclonal antibody produced by the hybridoma designated F 33 (ATCC No. HB 10155) .

6. A method of claim 4, wherein the sample of the malignant cell or tissue comprises human malignant cells or tissue.

7. A method of claim 4, wherein the sample of the malignant cell or tissue comprises carcinoma cells or tissue.

8. A method of claim 7, wherein the carcinoma cells or tissue comprise renal carcinoma cells or tissue.

9. A method of claim 8, wherein the renal carcinoma cells or tissue are human renal carcinoma cells or tissue.

10. A method of detecting the sensitivity of a malignant cell or tissue to alpha interferon therapy which comprises contacting a sample of the malignant cell or tissue with a monoclonal antibody which recognizes an epitope of gp 160 cell surface antigen under conditions such that an antibody-antigen complex is formed between the monoclonal antibody and the gp 160 cell surface antigen, if the antigen is present in the sample; and detecting any complex so formed, the presence of complex indicating that the malignant cell or tissue is resistant to alpha interferon therapy.

11. A method of claim 10, wherein the monoclonal antibody is the monoclonal antibody produced by the hybridoma designated F 33 (ATCC No. HB 10155).

12. A method of claim 10, wherein the sample of the malignant cell or tissue comprises human malignant cells or tissue.

13. A method of claim 10, wherein the sample of the malignant cell or tissue comprises carcinoma cells or tissue.

14. A method of claim 13, wherein the carcinoma cells or tissue comprise renal carcinoma cells or tissue.

15. A method of claim 14, wherein the renal carcinoma cells or tissue are human renal carcinoma cells or tissue.

16. A method of treating patients having tumors which do not express gp 160 cell surface antigen, which comprises administering to the patient an effective amount of alpha interferon, effective to inhibit the growth of the tumor.

17. A method of claim 16, wherein the gp 160 antigen has an epitope which is recognized by the monoclonal antibody produced by the hybridoma designated F 33 (HB 10155) .

18. A method of claim 16, wherein the tumor comprises carcinoma cells or tissue.

19. A method of claim 18, wherein the carcinoma cells or tissue comprise renal carcinoma cells or tissue.

20. A method of determining whether the growth of malignant cells or tissue will be inhibited by alpha interferon which comprises contacting a sample of the malignant cell or tissue with a monoclonal antibody which recognizes an epitope of gp 160 cell surface antigen under conditions such that an antibody-antigen complex is formed between the monoclonal antibody and the gp 160 cell surface antigen, if the antigen is present in the sample; and detecting any complex so formed, the absence of complex indicating that the growth of the malignant cell or tissue will be inhibited by alpha interferon.

21. A method of claim 20, wherein the monoclonal antibody is the monoclonal antibody produced by the hybridoma designated F 33 (ATCC No. HB 10155) .

22. A method of claim 20, wherein the sample of the malignant cell or tissue comprises human malignant cells or tissue.

23. A method of claim 20, wherein the sample of the malignant cell or tissue comprises carcinoma cells or tissue.

24. A method of claim 23, wherein the carcinoma cells or tissue comprise renal carcinoma cells or tissue.

25. A method of claim 24, wherein the renal carcinoma cells or tissue are human renal carcinoma cells or tissue.